Navigation Links
Covance Board Authorizes $250 Million Stock Buyback
Date:9/28/2010

PRINCETON, N.J., Sept. 28 /PRNewswire-FirstCall/ -- Covance Inc. (NYSE: CVD) said today that its Board of Directors has authorized the repurchase of up to $250 million of its outstanding common stock. This authorization is in addition to the approximately 800,000 shares remaining under the repurchase authorization announced in 2007 and currently represents nearly ten percent of the Company's common stock. Any purchases under this buyback would be dependent upon business and market conditions and other factors. The stock purchases may be made from time to time and may be made through a variety of methods including open market purchases, privately negotiated transactions, block trades, and 10b5-1 plans.

"This action reflects the confidence of the Board and management in the fundamental strengths and future outlook of Covance," said Joe Herring, Chairman and Chief Executive Officer of Covance.

About Covance

Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $1.8 billion, global operations in more than 30 countries, and more than 10,000 employees worldwide.  Information on Covance's products and services, recent press releases, and SEC filings can be obtained through its website at www.covance.com.

Statements contained in this press release, which are not historical facts, such as statements about prospective earnings, savings, revenue, operations, revenue and earnings growth and other financial results are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All such forward-looking statements including the statements contained herein regarding anticipated trends in the Company's business are based largely on manag
'/>"/>

SOURCE Covance Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Covance Announces Integrated Radiolabeled Clinical Pharmacology Studies
2. Covance Receives Highest Level of Phase I Accreditation
3. Covance Inc. Invites You to Join the Webcast of Its Fourth Quarter 2009 Financial Results Conference Call
4. Covance to Present at the 28th Annual J.P. Morgan Healthcare Conference
5. Rules-Based Medicine Forms Biomarker Alliance With Covance Inc.
6. Covance Enters Into a Biomarker Alliance With Rules-Based Medicine, Inc.
7. Covance to Present at Piper Jaffray 21st Annual Health Care Conference
8. Covance To Present At The 20th Annual Global Healthcare Services Conference
9. Covance To Present at the Deutsche Bank 35th Annual Health Care Conference
10. Covance to Present at Goldman Sachs 31st Annual Global Healthcare Conference
11. Covance to Present at William Blair & Companys 30th Annual Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... DUBLIN , Oct. 24, 2014 ... "Dental Equipment Market Current Trends, Opportunities - Global ... In this report, the global dental equipment ... geography. The dental systems and equipment market is expected ... equipment market during the forecast period (2014 to 2019). ...
(Date:10/25/2014)... , Oct. 24, 2014  America,s future engineers ... robotic competition at the  Medical Design and Manufacturing ... 29-30 th at the Minneapolis ... local student built robots from the "For Inspiration ... FIRST students and mentors will offer information to ...
(Date:10/25/2014)... , October 24, 2014 ... the addition of the "Global and Chinese ... their offering.      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... Report 2014 is a professional and in-depth study ... industry with a focus on the Chinese situation. ...
Breaking Medicine Technology:Dental Equipment Market Current Trends, Opportunities - Global Forecast to 2019 2Dental Equipment Market Current Trends, Opportunities - Global Forecast to 2019 3Local robotics teams compete - a "FIRST" at next week's MD&M Minneapolis- October 29-30th at the Minneapolis Convention Center 2Local robotics teams compete - a "FIRST" at next week's MD&M Minneapolis- October 29-30th at the Minneapolis Convention Center 3Global and Chinese Hemodialysis Concentrates Industry Report 2014 2Global and Chinese Hemodialysis Concentrates Industry Report 2014 3
... Quark siRNAs Examined Alone and in Combination ... Quark Pharmaceuticals, Inc., a,development-stage pharmaceutical company ... today announced that the,journal Cancer Research published ... target gene against non-small cell lung cancer ...
... Prophylaxis Treatment with Kogenate FS Reduces the,Risk of ... No Pre-Existing,Joint Damage, BERKELEY, Calif., Oct. 10 ... Food and Drug Administration (FDA) has,approved routine prophylaxis ... frequency of bleeding episodes and the risk of,joint ...
Cached Medicine Technology:Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy 2Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy 3Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy 4FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 2FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 3FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 4FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 5
(Date:10/25/2014)... -- A large influx of international aid is needed, ... of thousands of deaths from the widening Ebola crisis, ... Using a specially designed mathematical model, the researchers looked ... one densely populated county of hard-hit Liberia -- Montserrado ... The researchers said that if international aid isn,t delivered ...
(Date:10/25/2014)... Oct. 24, 2014 (HealthDay News) -- October,s shorter, darker ... seasonal affective disorder, according to an expert. ... may feel overly tired, lack motivation and even have ... can lead to suicide, said Dr. Angelos Halaris, a ... at Loyola University Chicago Stitch School of Medicine. ...
(Date:10/22/2014)... On October 22, CBS will air an ... both fictional and real. The Charles E Holman ... to advocacy and philanthropy in the battle against Morgellons ... to impart truth and clarity about this misunderstood and ... misconceptions about Morgellons Disease (MD) and most ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 For Dr. Iris ... make money; it’s an extension of her life’s mission. Her ... venture as the owner of FirstLight HomeCare, make it clear ... important to me that my work makes a difference in ... an entrepreneurial spirit, so after much research, I felt ready ...
(Date:10/22/2014)... 2014 Shriners Hospitals for Children® and ... the current location of Shriners Hospitals for Children - ... from the University of Kentucky Albert B. Chandler Hospital. ... center, owned and operated by Shriners Hospitals for Children, ... children and their families well into the future. , ...
Breaking Medicine News(10 mins):Health News:Experts Predict 'Catastrophic' Ebola Epidemic in West Africa if Aid Delayed 2Health News:Dark Days Here for Folks With Seasonal Depression 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 3Health News:Dr. Iris Hunter to Host Grand Opening of FirstLight HomeCare Tomorrow 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 3
... 26 John Williams,a shrimp fisherman and executive ... the House Subcommittee on Oversight and,Investigations of the ... criticized the Food and Drug Administration,s,(FDA) reliance on ... legislative actions., "On behalf of the U.S. ...
... Customers and ... Private Insurance Corporations, OAKLAND, Calif., Feb. 26 ... organized by the California,Nurses Association/National Nurses Organizing Committee that ... a,9/11 rescue worker; Donna Smith, who has recently joined ...
... Settlement on Outstanding Disputes, SPOKANE, Wash., Feb. ... Sandpoint, Idaho reached settlement on four,outstanding disputes. The ... Spokane, Washington., "This settlement is very important ... capably despite management,s refusal to negotiate a fair,contract," ...
... entertains sports world, KANSAS CITY, Mo., Feb. ... with Kansas City roots. A team of college ... premier,community for all athletes, fans, coaches and professionals., ... have a positive impact,on the entire athletic community," ...
... ARJO, Inc. announces the release,of two new lifts, and ... a unique open, twin mast design, and the SARA ... Twin has twin masts, which improve stability and weight,distribution, ... design.,All powered functions, including Powered DPS (Dynamic Positioning System),are ...
... of the Board of Directors; Daniel ... Operating Officer -, EXTON, Pa., Feb. 26 ViroPharma Incorporated,(Nasdaq: ... J.,Milano will succeed Michel de Rosen as president and chief executive,officer ... directors. Mr.,de Rosen, who has led the company as president and ...
Cached Medicine News:Health News:Testimony to Congress Denounces FDA Reliance on Self-Policing 2Health News:Michael Moore Defends 9/11 Rescue Workers and Criticizes Insurance Industry on California Nurses Association Press Call 2Health News:Nurses Convince Hospital to Return to Bargaining Table 2Health News:AthletixNation.com Launches Sports Website and Community Programs 2Health News:Vincent J. Milano to Succeed Michel de Rosen as President and Chief Executive Officer of ViroPharma 2Health News:Vincent J. Milano to Succeed Michel de Rosen as President and Chief Executive Officer of ViroPharma 3
Synchron CX3 Delta is a critical care clinical system, providing unparalleled testing speed for the most frequently ordered chemistries-Glucose, BUN, Creatinine, Sodium, Potassium Chloride, CO2 Calci...
Iron (Total/Ferene). Storage temp: 15 - 30 C. Linearity: 0 - 500 ug/dl. Expected values: from males 60 - 160 ug/dl, from females 43 - 140 ug/dl. Available with Calibrator and Number of test are 120....
For the quantitative determination of iron, total iron-binding capacity in human serum....
HDL Cholesterol, liquid....
Medicine Products: